Patient preference and type of chemotherapy for mCRPC

In another presentation from the ESMO meeting in  Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial  exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …

To screen or not to screen: an Australian “discrete choice experiment”

The question of whether men should be regularly screened for risk of prostate cancer through the use of the PSA test is (at least) controversial … READ MORE …

Patients and urologists both prefer active surveillance (maybe, in the Netherlands)

It has been a while since we saw data from a contemporary survey of the views of urologists and patients on their preferences for appropriate management of early stage, localized prostate cancer. … READ MORE …

Treatment decision-making and subsequent outcomes: a survey among African American survivors

The degree to which individual patients with prostate cancer wish to participate in making decisions about their treatment varies considerably, and it is important for health professionals to understand the degree to which each individual patient wants to be an active participant in these decisions. … READ MORE …

The Monday news update: March 2, 2009

New reports today address:

  • Positive surgical margins: RALP vs. RRP
  • Circulating tumor cells levels and survival of castration-resistant prostate cancer patients
  • Patient preference and management of post-surgical incontinence … READ MORE …